Clinical Outcomes Of Cataract Surgeries Using A Next-Generation Extended Depth-Of-Focus Intraocular Lens
Published 2025 - 43rd Congress of the ESCRS
Reference: PP10.05 | Type: Free paper | DOI: 10.82333/ezmk-0h97
Authors: David Wackerberg* 1 , Jenny Gyllén 1 , Birgitte Haargaard 2 , Alf Nyström 1 , Arzu Karatepe-Hashas 1 , Anna Linnarsson Wiklund 3 , Eric Trocmé 4 , Ulrika Kjellström 5 , Kristina Tornqvist 5 , Gunilla Magnusson 1
1Department of Clinical Neuroscience,Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden,Göteborg,Sweden, 2Private Ophthalmologist,Private Ophthalmologist,Copenhagen,Denmark, 3Department of Paediatric Ophthalmology and Strabismus,St Erik Eye Hospital, Stockholm, Sweden,Stockholm,Sweden, 4Department of Clinical Neuroscience,Division of Ophthalmology and Vision, Karolinska Institute, St Erik Eye Hospital, Stockholm, Sweden,Stockholm,Sweden, 5Department of Clinical Sciences,Ophthalmology, Skåne University Hospital, Lund University, Lund, Sweden.,Lund,Sweden
Purpose
A new purely refractive extended depth-of-focus (EDOF) intraocular lens (IOL) was designed with a continuous change in power to bridge the gap between monofocal and multifocal IOLs. Although a few studies have reported optical bench or clinical outcomes with the new refractive EDOF IOL, visual performance and patient satisfaction results in real-world clinical settings remain largely unknown. This study aimed to evaluate the real-world clinical outcomes of the new EDOF IOL compared with those of the enhanced monofocal IOL.
Setting
This is a single-center, respective study conducted in Severance Eye Hospital, Yonsei University College of medicine, Seoul, Korea. We retrospectively reviewed the medical charts and clinical data of patients who underwent bilateral cataract surgery between June 2020 and May 2024.
Methods
This retrospective analysis was conducted on 100 eyes from 50 patients undergoing bilateral cataract surgery with either the PureSee™ (ZEN00V) or Eyhance™ (ICB00) IOL. Subjects were matched by age. Visual acuity, binocular defocus curves, monocular contrast sensitivity, and patient-reported outcomes on photic phenomena, spectacle independence and satisfaction were evaluated three months postoperatively.
Results
The ZEN00V group demonstrated superior uncorrected intermediate (0.11 ± 0.08 vs. 0.17 ± 0.11 logMAR, p <0.001) and near visual acuity (0.25 ± 0.08 vs. 0.31±0.13 logMAR, p = 0.002) compared to the ICB00 group, with comparable distance visual acuity. The ZEN00V group generally outperformed the ICB00 IOL in the binocular defocus test. Contrast sensitivity was comparable between the two groups across all spatial frequencies under both mesopic and photopic conditions. While photic phenomena were more frequent in the ZEN00V group, spectacle dependence was significantly lower for near vision (36% vs. 80%) and comparable for intermediate and far vision.
Conclusions
The PureSee™ EDOF IOL demonstrated enhanced intermediate and near vision with minimal compromise to distance vision or contrast sensitivity. It also provided significant spectacle independence and patient satisfaction, making it a promising option for presbyopia correction. Additionally, our results demonstrated the reproducibility of preclinical simulations and randomized clinical trial findings using real-world clinical data. The TECNIS Puresee™ IOL is expected to be a valuable option for cataract surgeons, offering excellent distance and intermediate vision and functional near vision with acceptable photic phenomena.